Edition:
United States

bluebird bio Inc (BLUE.OQ)

BLUE.OQ on NASDAQ Stock Exchange Global Select Market

182.95USD
15 Dec 2017
Change (% chg)

$-1.40 (-0.76%)
Prev Close
$184.35
Open
$184.35
Day's High
$185.00
Day's Low
$177.50
Volume
952,116
Avg. Vol
279,205
52-wk High
$222.00
52-wk Low
$61.00

Select another date:

Tue, Dec 12 2017

BRIEF-Bluebird Bio Prices Public Offering Of 3.2 Mln Shares At $185/Share

* BLUEBIRD BIO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Bluebird Bio Announces Proposed Public Offering Of Common Stock

* BLUEBIRD BIO ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-bluebird bio And TC BioPharm Announce Strategic Collaboration

* BLUEBIRD BIO AND TC BIOPHARM ANNOUNCE STRATEGIC COLLABORATION TO RESEARCH AND DEVELOP GAMMA DELTA CAR T CELL PRODUCT CANDIDATES FOR CANCER IMMUNOTHERAPY

BRIEF-Bluebird Bio Acquires Manufacturing Facility In North Carolina

* BLUEBIRD BIO ACQUIRES MANUFACTURING FACILITY IN NORTH CAROLINA AND EXECUTES MULTIPLE GLOBAL SUPPLY AGREEMENTS TO ENHANCE ABILITY TO DELIVER GENE THERAPIES TO PATIENTS Source text for Eikon: Further company coverage:

BRIEF-Bluebird Bio says to receive $15 mln option exercise payment from Celgene​

* Bluebird Bio Inc - to receive $15 million option exercise payment from Celgene​

BRIEF-Bluebird Bio appoints Mary Lynne Hedley, Ph.D. to board of directors

* Bluebird Bio appoints Mary Lynne Hedley, Ph.D. to board of directors Source text for Eikon: Further company coverage:

BRIEF-Bluebird Bio Q2 net loss per share $1.73

* Bluebird Bio reports second quarter 2017 financial results and recent operational progress

BRIEF-Bluebird Bio announces pricing of public offering of common stock

* Bluebird Bio announces pricing of public offering of common stock

BRIEF-Bluebird bio reports updated clinical data from starbeam study

* bluebird bio Inc says on June 26, co reported updated clinical data from starbeam study clinical study of its lenti-d product candidate - sec filing

Select another date: